Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Jin, Hua; Jang, Yoonjeong; Cheng, Nian; Li, Qing; Cui, Peng-Fei; Zhou, Zhi-Wei; Jiang, Hu-Lin; Cho, Myung-Haing; Westover, Kenneth D.; Tan, Qun-You; Xu, Cheng-Xiong
- Source:
Journal of Experimental & Clinical Cancer Research (17569966); 4/15/2019, Vol. 38 Issue 1, pN.PAG-N.PAG, 1p
- Subject Terms:
- Additional Information
- Abstract:
Background: miRNAs play crucial role in the progression of K-Ras-mutated nonsmall cell lung cancer (NSCLC). However, most studies have focused on miRNAs that target K-Ras. Here, we investigated miRNAs regulated by mutant K-Ras and their functions. Methods: miRNAs regulated by mutant K-Ras were screened using miRNA arrays. miR-199b expression levels were measured by qRT-PCR. The protein expression levels were measured using Western blot and immunohistochemistry. The effects of miR-199b on NSCLC were examined both in vitro and in vivo by overexpressing or inhibiting miR-199b. DNA methylation was measured by bisulfite sequencing. Results: An inverse correlation was observed between K-Ras mutation status and miR-199b levels in NSCLC specimens and cell lines. The inhibition of miR-199b stimulated NSCLC growth and metastasis, while restoration of miR-199b suppressed K-Ras mutation-driven lung tumorigenesis as well as K-Ras-mutated NSCLC growth and metastasis. miR-199b inactivated ERK and Akt pathways by targeting K-Ras, KSR2, PIK3R1, Akt1, and Rheb1. Furthermore, we determined that mutant K-Ras inhibits miR-199b expression by increasing miR-199b promoter methylation. Conclusion: Our findings suggest that mutant K-Ras plays an oncogenic role through downregulating miR-199b in NSCLC and that overexpression of miR-199b is a novel strategy for the treatment of K-Ras-mutated NSCLC. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of Journal of Experimental & Clinical Cancer Research (17569966) is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.